HC Wainwright & Co. Reiterates Buy on Tango Therapeutics, Maintains $68 Price Target
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsReiterationPrice Target
HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $68 price target.
HC Wainwright & Co. analyst Robert Burns reiterates Tango Therapeutics (NASDAQ:TNGX) with a Buy and maintains $68 price target.